Ibrahim Fatih Cengiz, BSc, MSc, PhD, is a researcher in Tissue Engineering and Regenerative Medicine, with a particular interest in orthopedics, bioimaging, and preclinical models. He has been part of the 3B’s Research Group, University of Minho, Portugal, for over a decade. His academic background includes a PhD in Tissue Engineering, Regenerative Medicine, and Stem Cells, and an MSc in Biomedical Engineering. He has been a Marie Sklodowska-Curie Fellow. Dr. Cengiz has contributed to around 200 scientific outputs, including papers, book chapters, and communications. His research focuses on developing solutions to improve musculoskeletal health, and he has contributed to advances in meniscus tissue engineering.J. Miguel Oliveira BSc, PhD, FBSE is a Principal Investigator with Habilitation at the 3B's Research Group, member of the PT Government Associate Laboratory ICVS/3B’s and Institute 3Bs (I3Bs), University of Minho (Portugal). Over the years he has focused his work on the field of biomaterials for tissue engineering, nanomedicine, stem cells, and cell/drug delivery. He also set up a new research line within the ICVS/3B’s on 3D in vitro models for cancer research. He has been awarded several prizes including the prestigious “Investigador FCT 2012 and Investigador FCT 2015” attributed by FCT (Portugal), and Jean Leray Award 2015 from European Society for Biomaterials for Young Scientists for Outstanding Contributions within the field of Biomaterials.Rui L. Reis is the Dean/President of I3Bs – Research Institute for Biomaterials, Biodegradables and Biomimetics, founding Director of the 3B’s Research Group at the University of Minho, Full Professor of Tissue Engineering, Regenerative Medicine, Biomaterials and Stem Cells, the CEO of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, and the Director of the PT Government Associate Laboratory ICVS/3Bs from the University of Minho (Portugal). Prof. Reis was awarded with the IET Harvey Engineering Research Prize to create reliable breakthrough 3D engineered functional cancer disease models for an improved prediction and efficacy of cancer drugs.